Perioperative Therapy for Hepatocellular Carcinoma

Summary

This study aims to observe and evaluate the efficacy and safety of the perioperative multidisciplinary therapy that combines the preoperative transarterial chemoembolization(TACE) and the anti-programmed-death-1 antibody (anti-PD-1) Sintilimab Injection with or without radiotherapy of vein tumor thrombus followed by postoperative anti-PD-1 injection in the treatment of technically resectable hepatocellular carcinoma patients with vein thrombosis.

Timeline

Start

2020-12-26

Primary completion

2021-10-01

Completion

2021-12-01

Outcome

Outcome not reported

Stopped: “The treatment efficacy was not satisfactory.”

Drugs

Indications